Dignify Therapeutics
Research Triangle Park, US · Founded 2013 · Delaware LLC · 2 known investors
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function. It operates in the biotechnology and pharmaceutical space focused on therapeutics for people with impaired bladder and bowel control.
Founders & leadership
Dignify Therapeutics was founded in 2013 by Karl B Thor, Edward C Burgard, and Karl Thor.
KB
Karl B ThorCo-founder
EC
Edward C BurgardCo-founder
KT
Karl Thor
BW
Benny WardExecutive
Board
FE
DJ
Daniel J RiccaBoard director
EV
Ebrahim VersiBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$3.4M disclosed across 1 round · 2014
▶$3.4MraisedFeb 2015 · 7 investors · PharmaceuticalsRule 506(c)
▶$3.4MraisedFeb 2015 · 7 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Mary KatofiascPromoter
- Tatyana TouzovaPromoter
- Karl B ThorExecutive Officer, Director, Promoter
- Edward C BurgardExecutive Officer, Director, Promoter
- Benny WardExecutive Officer, Director, Promoter
- Daniel J RiccaDirector, Promoter
- Ebrahim VersiDirector, Promoter
- Florenta Aura KullmannPromoter
- Fred EshelmanDirector
- Venkateswarlu KarichetiPromoter
- Lesley MarsonPromoter
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Minimum investment
- $100K
- Proceeds to insiders
- $1M
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Industries52 shared keywordsJ.P. Morgan is a global financial services firm serving corporations and individuals in more than 100 countries, offering investment research, tools, data, analytics, and advisory services. It supports institutional investors, asset and fund managers, hedge funds, broker dealers, and equity issuers with liquidity, fixed income strategies, and equity compensation solutions.
bio51 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Forbion44 shared keywordsForbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health. It integrates ESG principles into its investments, targeting patient impact, societal benefits, and sustainability.
Mmm Online44 shared keywordsMM+M (Medical Marketing and Media) is a trade media outlet covering the healthcare marketing and advertising industry, publishing rankings and profiles such as its annual Agency Network Family Tree and lists of top healthcare agencies.
Syneos Health44 shared keywordsSyneos Health is a contract research and commercialization services company that supports biopharmaceutical companies in drug development, regulatory affairs, and market launch across therapeutic areas. The firm employs over 26,000 specialists including MDs and PhDs to help clients develop and commercialize pharmaceuticals globally.
Companies competing with Dignify Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 18 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $541.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $394.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $244.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $901.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $269.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $275.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $199.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $159.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Dignify Therapeutics do?
- Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function. It operates in the biotechnology and pharmaceutical space focused on therapeutics for people with impaired bladder and bowel control.
- Who founded Dignify Therapeutics?
- Dignify Therapeutics was founded by Karl B Thor, Edward C Burgard, Karl Thor in 2013.
- Who are Dignify Therapeutics's investors?
- Dignify Therapeutics's investors include Eshelman Ventures, LLC, RA Capital.
- How much funding has Dignify Therapeutics raised?
- Dignify Therapeutics has disclosed $3.4M raised across 1 round.
- Where is Dignify Therapeutics headquartered?
- Dignify Therapeutics is headquartered in Research Triangle Park, US.